Young-jin Kim

Chairman

5 past transactions

WELT

Series C in 2024
WELT is a stylish smart belt designed for both fashion and healthcare purposes. It tracks waist size, steps taken, sitting time, and overeating habits, providing personalized health insights via Bluetooth to its accompanying app.

Spark Biopharma

Series B in 2021
SPARK BioPharma Co., Ltd. was established in Seoul National University in January 2016 based on the unique drug molecule diversity technology, the image-based screening technology using the unique fluorescent skeleton probe, and the target protein identification technology in the initial drug development stage. We are currently exploring and developing new drug candidates using these three core technologies, and we will continue to accelerate the development of new drugs and increase the success rate through strategic cooperation research with domestic and overseas research institutes and pharmaceutical institutions. '

WELT

Series B in 2021
WELT is a stylish smart belt designed for both fashion and healthcare purposes. It tracks waist size, steps taken, sitting time, and overeating habits, providing personalized health insights via Bluetooth to its accompanying app.

BiomX

Series B in 2019
BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Rezolute

Post in 2019
Rezolute Inc., established in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company's primary product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b trials for treating congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical stages for diabetic macular edema treatment. The company aims to improve existing standards of care by applying proprietary formulation and manufacturing capabilities to known molecules.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.